Your browser doesn't support javascript.
loading
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
Plum-Mörschel, Leona; Klein, Oliver; Singh, Gursharan; Murugesan, Sundara Moorthi Nainar; Marwah, Ashwani; Sharma, Nirant; Panda, Jayanti; Loganathan, Subramanian; Lakshmi, Gopu Chandrasekharan; Athalye, Sandeep N.
Afiliação
  • Plum-Mörschel L; Profil, Mainz, Germany.
  • Klein O; Profil, Neuss, Germany.
  • Singh G; Biocon Biologics Ltd., Bengaluru, India.
  • Murugesan SMN; Biocon Biologics Ltd., Bengaluru, India.
  • Marwah A; Biocon Biologics Ltd., Bengaluru, India.
  • Sharma N; Biocon Biologics Ltd., Bengaluru, India.
  • Panda J; Biocon Biologics Ltd., Bengaluru, India.
  • Loganathan S; Biocon Biologics Ltd., Bengaluru, India.
  • Lakshmi GC; Biocon Biologics Ltd., Bengaluru, India.
  • Athalye SN; Biocon Biologics Ltd., Bengaluru, India.
Diabetes Obes Metab ; 24(9): 1819-1828, 2022 09.
Article em En | MEDLINE | ID: mdl-35589611
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares / Insulina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares / Insulina Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article